<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03105401</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL17_0137</org_study_id>
    <nct_id>NCT03105401</nct_id>
  </id_info>
  <brief_title>Phenomenological and Psychopathological Factors Associated to Hallucinations in Parkinson's Disease</brief_title>
  <acronym>HALLUPARK</acronym>
  <official_title>Phenomenological and Psychopathological Factors Associated to Hallucinations in Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to describe hallucinations prevalence in a sample of patients affected by&#xD;
      Parkinson's disease and consulting in an outpatient facility.&#xD;
&#xD;
      An unique one hour interview will be offered to volunteers patients. Patients participating&#xD;
      to the study will be asked to answer a semi-structured questionnaire searching for&#xD;
      hallucinations of all modalities, minor psychotic symptoms and delusions. Psychometric scales&#xD;
      will be assessed to search for depressive symptoms, cognitive impairment and specific&#xD;
      personality characteristics.&#xD;
&#xD;
      The study hypothesis is that hallucinations prevalence in Parkinson's disease is&#xD;
      underestimated and is higher than usually described in the scientific literature when all&#xD;
      hallucinations modalities and minor hallucinatory phenomenons are searched for.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    recruitment difficulties&#xD;
  </why_stopped>
  <start_date type="Actual">May 15, 2017</start_date>
  <completion_date type="Actual">April 25, 2018</completion_date>
  <primary_completion_date type="Actual">April 25, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hallucinations Prevalence</measure>
    <time_frame>1 hour</time_frame>
    <description>Semi-structured questionnaire precisely describing hallucinations of all modalities and their characteristics, as well as minor hallucinations and delusions. Binary Yes/No possible answers.&#xD;
Unique 1 hour interview to assess semi-structured questionnaire for primary outcome measurement, and psychometric scales.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">32</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Patients affected by Parkinson's disease</arm_group_label>
    <description>Outpatients affected by Parkinson's Disease consulting in neurology can be included if volunteer</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Assessment of hallucinations in Parkinson's disease</intervention_name>
    <description>Patients participating to the study will be asked to answer a semi-structured questionnaire searching for hallucinations of all modalities, minor psychotic symptoms and delusions. Psychometric scales will be assessed to search for depressive symptoms, cognitive impairment and specific personality characteristics.</description>
    <arm_group_label>Patients affected by Parkinson's disease</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Outpatients affected by Parkinson's Disease consulting in neurology can be included if&#xD;
        volunteer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years-old&#xD;
&#xD;
          -  Absence of opposition from the patient himself/herself or his/her legal representant&#xD;
             for his/her participation to the study&#xD;
&#xD;
          -  Patient without superior age limit with a diagnosis of Parkinson's disease made&#xD;
             according to the UKPDSBB criteria (UK Parkinson's Disease Society Brain Bank clinical&#xD;
             diagnostic criteria)&#xD;
&#xD;
          -  Outpatient consulting in neurology at the Charpennes'hospital&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Opposition to the study&#xD;
&#xD;
          -  Deafness or blindness which could compromise the interview&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing XIE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital des Charpennes. Centre de Recherche Clinique - vieillissement, cerveau, fragilité</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital des Charpennes. Centre de Recherche Clinique - vieillissement, cerveau, fragilité</name>
      <address>
        <city>Villeurbanne</city>
        <zip>69100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>April 4, 2017</study_first_submitted>
  <study_first_submitted_qc>April 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2017</study_first_posted>
  <last_update_submitted>January 15, 2019</last_update_submitted>
  <last_update_submitted_qc>January 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Hallucinations</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

